时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
Islet transplantation effectively restores physiologic glycemic regulation in a subset of individuals living with type 1 diabetes; however, lifelong systemic immunosuppression remains a major barrier to broader patient inclusion. Herein, we explored the use of a localized drug delivery system to preserve islet allograft function, circumventing systemic immunosuppression. Rapamycin (Rapa) was effectively encapsulated within poly(lactic-co-glycolic acid) microparticles (MP), which facilitated sustained and localized drug release to the islet grafts, modulating the immune environment and significantly prolonging allograft survival (p<0.05). Long-term outcomes were further enhanced when Rapa-MP …
对本项目的价值
中等价值：属「营养感知—自噬—蛋白稳态轴」方向；干预策略与临床试验栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.2/5（★★☆☆☆）
全文不可及原因
无 PMCID 且 OpenAlex / Unpaywall 未提供可下载 OA PDF
原文题录
- 中文题名：雷帕霉素洗脱 PLGA 微粒局部免疫调节促进小鼠胰岛移植存活并诱导操作性耐受
- 英文标题：Graft Localized Immunomodulation with Rapamycin-Eluting PLGA Microparticles Promotes Murine Islet Allograft Survival and Induces Operational Tolerance.
- 期刊与标识：Am J Transplant · PMID 42966570 · DOI 10.1016/j.ajt.2026.10.025 · EDAT 2026-10-31